In the May Antibody Update, you can expect to find news of an enzyme inhibitor that increases the efficacy of anti-PD-1 Immunotherapy, the generation of induced pluripotent blood stem cells, and the rapid employment of the latest Ebola vaccine in the Democratic Republic of the Congo. Learn more at ProSci.
Read More
Immune system checkpoint inhibition may not always be the perfect way to target cancer. Why is it that some patients do not respond positively to certain immunotherapy treatments like Ipilimumab? This blog takes into account the immune system's convoluted nature to understand how immune checkpoint antibodies may not be the problem, and how personalized medicine could help.
Read MoreWednesday, February 15, 2017 10:00:00 AM America/Los_Angeles
Comments |
Posted in Science Corner
By Yousif Slaiwa
A Brief Introduction to PD-1 Antibodies and Immunotherapy
T-cell PD-1/PD-L1 immunotherapy is one of the newest frontiers of cancer treatment and is changing the industry. Learn more about immunotherapy and its method of action in this blog.
Tuesday, February 16, 2016 12:20:00 PM America/Los_Angeles
Comments |
Posted in Research Highlights
By Jonathan Felix
December 2015: The Antibody Update
This month's Antibody Update includes the highlights of the Antibody Engineering and Therapeutics conference, Jimmy Carter's cancer remission, and another cancer antibody designed to target CD-47.
